Abstract
Obesity adversely affects outcome in pediatric acute lymphocytic leukemia and acute myeloid leukemia (AML). We asked if obesity, measured by body mass index (BMI), affected outcome in 329 adult AML patients treated with high-dose cytarabine and idarubicin-containing regimens administered according to actual body weight. Age ≥ 60, unfavorable karyotype, secondary AML, and positive smoking status had adverse impact on overall survival in a multivariate analysis, while BMI did not. We conclude that high BMI should not be a barrier to administer high-dose cytarabine-containing regimens for AML induction.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adolescent
-
Adult
-
Aged
-
Aged, 80 and over
-
Antibiotics, Antineoplastic / therapeutic use*
-
Antimetabolites, Antineoplastic / therapeutic use*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Body Mass Index
-
Clinical Trials, Phase I as Topic
-
Cytarabine / therapeutic use*
-
Databases, Factual
-
Female
-
Humans
-
Idarubicin / therapeutic use*
-
Kaplan-Meier Estimate
-
Leukemia, Myeloid, Acute / drug therapy*
-
Leukemia, Myeloid, Acute / mortality
-
Leukemia, Myeloid, Acute / physiopathology*
-
Male
-
Middle Aged
-
Obesity / physiopathology*
-
Retrospective Studies
-
Treatment Outcome
-
Young Adult
Substances
-
Antibiotics, Antineoplastic
-
Antimetabolites, Antineoplastic
-
Cytarabine
-
Idarubicin